The FDA has unveiled a significant plan to phase out animal testing requirements for monoclonal antibodies and other drugs, marking a monumental shift in drug development practices. This initiative aims to replace traditional animal testing models with alternative methods, potentially including AI-driven experiments. FDA Commissioner has emphasized that this change is beneficial for both ethics and public health. The announcement has prompted a mixture of reactions in the financial markets, with stocks for companies heavily reliant on animal testing, such as Charles River Laboratories and Inotiv, experiencing significant declines, while companies involved in health care technology, like Certara, saw gains. This movement aligns with recent congressional discussions on reducing animal testing across various federal agencies, including the EPA.